07:35 AM EDT, 06/26/2025 (MT Newswires) -- Viatris ( VTRS ) said Thursday that a late-stage trial evaluating MR-141 as a treatment for presbyopia has met its primary and all secondary endpoints.

The company said MR-141 showed rapid sustained improvement in near visual acuity without compromising distance vision. The study found that MR-141's safety profile was consistent with previous clinical trials, with no treatment-related serious adverse events identified, Viatris ( VTRS ) said.

Viatris ( VTRS ) said it is plans the submit an application to the US Food and Drug Administration in the second half of this year.

The company's shares were up 1.5% in recent premarket activity.